mecasermin rinfabate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
insulin-like growth factors	5197	478166-15-3

Description:

Molecule	Description
Synonyms: mecasermin rinfabate mecasermin rinfabate recombinant	Mecasermin rinfabate [rDNA origin] injection is an aqueous solution for injection containing a binary protein complex of human insulin-like growth factor-1 (rhIGF-1) and human insulin-like growth factor-binding protein-3 (rhIGFBP-3), both produced by recombinant DNA technology. The primary pharmacologic effect of IGF-1 in children is the promotion of linear growth. Secondary pharmacologic actions of IGF-1 include other anabolic effects, insulin sensitization, and insulin-like effects. There are no known direct growth-promoting effects of IGFBP-3. The primary effect of IGFBP-3 in the mecasermin rinfabate complex is the modulation of IGF-1 action. Molecular weight: 36404.45 Formula: C1562H2485N465O485S27 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: 12082.97 ALOGS: ROTB: None

Molecule

Description

Synonyms:

mecasermin rinfabate
mecasermin rinfabate recombinant

Mecasermin rinfabate [rDNA origin] injection is an aqueous solution for injection containing a binary protein complex of human insulin-like growth factor-1 (rhIGF-1) and human insulin-like growth factor-binding protein-3 (rhIGFBP-3), both produced by recombinant DNA technology. The primary pharmacologic effect of IGF-1 in children is the promotion of linear growth. Secondary pharmacologic actions of IGF-1 include other anabolic effects, insulin sensitization, and insulin-like effects. There are no known direct growth-promoting effects of IGFBP-3. The primary effect of IGFBP-3 in the mecasermin rinfabate complex is the modulation of IGF-1 action.

Molecular weight: 36404.45
Formula: C1562H2485N465O485S27
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA: 12082.97
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Dec. 12, 2005	FDA	INSMED

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	H01AC05	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES Somatropin and somatropin agonists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Laron-type isolated somatotropin defect	indication	38196001	DOID:9521

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
NZ8M50KKRG	UNII
4025086	VANDF
C1696547	UMLSCUI
CHEMBL1201717	ChEMBL_ID
DB14751	DRUGBANK_ID
D04870	KEGG_DRUG
8437	INN_ID
20793	MMSL
d05692	MMSL
011373	NDDF
422284004	SNOMEDCT_US
616877	RXNORM

Pharmaceutical products:

None